CABA

Cabaletta Bio Q4 and FY 2025 Financial Review

Cabaletta Bio Q4 and FY 2025 Financial Review

Company Overview Cabaletta Bio is a late-stage clinical biotechnology company focused on developing targeted cell therapies specifically for patients with…